These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

516 related items for PubMed ID: 16951389

  • 1. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.
    Gonzalez-Angulo AM, Hortobágyi GN, Esteva FJ.
    Oncologist; 2006 Sep; 11(8):857-67. PubMed ID: 16951389
    [Abstract] [Full Text] [Related]

  • 2. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
    Emens LA.
    Am J Ther; 2005 Sep; 12(3):243-53. PubMed ID: 15891269
    [Abstract] [Full Text] [Related]

  • 3. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.
    Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV.
    BMC Cancer; 2007 Aug 08; 7():153. PubMed ID: 17686164
    [Abstract] [Full Text] [Related]

  • 4. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
    Pectasides D, Gaglia A, Arapantoni-Dadioti P, Bobota A, Valavanis C, Kostopoulou V, Mylonakis N, Karabelis A, Pectasides M, Economopoulos T.
    Anticancer Res; 2006 Aug 08; 26(1B):647-53. PubMed ID: 16739334
    [Abstract] [Full Text] [Related]

  • 5. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
    Menendez JA, Vellon L, Lupu R.
    Med Hypotheses; 2005 Aug 08; 64(5):997-1001. PubMed ID: 15780499
    [Abstract] [Full Text] [Related]

  • 6. HER-2/neu expression in primary and metastatic breast cancer.
    Lower EE, Glass E, Blau R, Harman S.
    Breast Cancer Res Treat; 2009 Jan 08; 113(2):301-6. PubMed ID: 18273700
    [Abstract] [Full Text] [Related]

  • 7. [Use of trastuzumab in the therapy of breast cancer].
    Riemer AB, Zielinski CC.
    Ther Umsch; 2008 Apr 08; 65(4):217-22. PubMed ID: 18622914
    [Abstract] [Full Text] [Related]

  • 8. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    Baselga J, Perez EA, Pienkowski T, Bell R.
    Oncologist; 2006 Apr 08; 11 Suppl 1():4-12. PubMed ID: 16971734
    [Abstract] [Full Text] [Related]

  • 9. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies.
    Singer CF, Köstler WJ, Hudelist G.
    Biochim Biophys Acta; 2008 Dec 08; 1786(2):105-13. PubMed ID: 18375208
    [Abstract] [Full Text] [Related]

  • 10. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
    Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP, Luftner D, Ghani F.
    Breast Cancer Res; 2005 Dec 08; 7(4):R436-43. PubMed ID: 15987448
    [Abstract] [Full Text] [Related]

  • 11. [HER-2/neu positive breast cancer: how to prescribe adjuvant trastuzumab (Herceptin)?].
    Belkacémi Y, Gligorov J, Mauriac L, Azria D.
    Bull Cancer; 2006 Oct 08; 93(10):991-9. PubMed ID: 17074658
    [Abstract] [Full Text] [Related]

  • 12. Targeting Her-2/neu in breast cancer: as easy as this!
    Azim H, Azim HA.
    Oncology; 2008 Oct 08; 74(3-4):150-7. PubMed ID: 18708732
    [Abstract] [Full Text] [Related]

  • 13. HER2/neu role in breast cancer: from a prognostic foe to a predictive friend.
    Ferretti G, Felici A, Papaldo P, Fabi A, Cognetti F.
    Curr Opin Obstet Gynecol; 2007 Feb 08; 19(1):56-62. PubMed ID: 17218853
    [Abstract] [Full Text] [Related]

  • 14. [Herceptin therapy in breast cancer: new indication?].
    Lebeau A.
    Verh Dtsch Ges Pathol; 2006 Feb 08; 90():99-106. PubMed ID: 17867585
    [Abstract] [Full Text] [Related]

  • 15. Serum EGFR levels and efficacy of trastuzumab-based therapy in patients with metastatic breast cancer.
    Hudelist G, Köstler WJ, Gschwantler-Kaulich D, Czerwenka K, Kubista E, Müller R, Helmy S, Manavi M, Zielinski CC, Singer CF.
    Eur J Cancer; 2006 Jan 08; 42(2):186-92. PubMed ID: 16326100
    [Abstract] [Full Text] [Related]

  • 16. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M.
    Orv Hetil; 2001 Nov 18; 142(46):2563-8. PubMed ID: 11770175
    [Abstract] [Full Text] [Related]

  • 17. [A retrospective analysis of trastuzumab-based therapy in metastatic breast cancer patients at Masaryk Memorial Cancer Institute. Identification of predictive factors].
    Svoboda M, Grell P, Simícková M, Fabian P, Petráková K, Palácová M, Macková D, Trojanec R, Hajdúch M, Pavlík T, Nenutil R, Vyzula R.
    Klin Onkol; 2008 Nov 18; 21(6):348-58. PubMed ID: 19382598
    [Abstract] [Full Text] [Related]

  • 18. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
    Castrellon AB, Glück S.
    Clin Adv Hematol Oncol; 2008 Sep 18; 6(9):666-72. PubMed ID: 18827789
    [Abstract] [Full Text] [Related]

  • 19. Hidden HER-2/neu-positive breast cancer: how to maximize detection.
    Carney WP.
    IDrugs; 2009 Apr 18; 12(4):238-42. PubMed ID: 19350468
    [Abstract] [Full Text] [Related]

  • 20. Progression and treatment of HER2-positive breast cancer.
    Davoli A, Hocevar BA, Brown TL.
    Cancer Chemother Pharmacol; 2010 Mar 18; 65(4):611-23. PubMed ID: 20087739
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.